Abnormal Brain Cell Type Leads to Parkinson’s-Related Neurodegeneration, Study Contends

Scientists have found that an abnormal version of brain cells called astrocytes contribute to the accumulation of alpha-synuclein protein, the main component of Parkinson’s disease hallmark Lewy bodies. Their study, “Patient-specific iPSC-derived astrocytes contribute to non-cell autonomous neurodegeneration in Parkinson’s disease,” was published in Stem Cell Reports. Parkinson’s disease is linked to degeneration of the

Genetic Variant Predetermines Risk of Cognitive Decline in Parkinson’s, Research Suggests

Researchers have found that Parkinson’s patients whose cognitive ability is intact, but who have a specific genetic variant, have significantly less gray matter in the regions of their brain that are related to dementia. The study with that finding, “Reduced gray matter volume in cognitively preserved COMT 158Val/Val Parkinson’s disease patients and its association with cognitive decline,”

Advanced PD and Palliative Care in the 21st Century

1.What is Palliative Care? 2.The Care Team Role 3.Managing Pain 4.Reducing Side Effects        5.Planning Advance Care 6.Conclusion Palliative care is a holistic, team-based approach to managing chronic health conditions, such as Parkinson’s disease (PD). Palliative care specialists champion quality of life and can be central to navigating the challenges of PD from initial diagnosis, onward. Most

Changes in Gait, Cognition May Be Early Signs of Idiopathic Parkinson’s, Research Suggests

Changes in gait and cognition precede a diagnosis of idiopathic (without known cause) Parkinson’s disease, and may occur earlier than typical non-motor symptoms, a study has found. The study, “Prediagnostic markers of idiopathic Parkinson’s disease: Gait, visuospatial ability and executive function,” was published in Gait & Posture. Motor symptoms in idiopathic Parkinson’s disease (IPD) are identified relatively late in the

Inbrija Approved in US to Treat Off Periods in Parkinson’s Patients on Carbidopa/Levodopa

The U.S. Food and Drug Administration has approved Inbrija (levodopa inhalation powder)‎ for the treatment of Parkinson’s off periods in patients on a carbidopa/levodopa regimen. Acorda Therapeutics’ therapy is expected to be available by prescription in the first quarter of 2019. It will be distributed through a network of specialty pharmacies in the U.S. “Today’s

Gout May Increase Parkinson’s Risk in Older People, Study of US Medicare Data Suggests

Gout appears to be associated with a higher risk of incident Parkinson’s disease in older adults, according to a study that looked at Medicare data in the U.S. The study, “Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data” was published in BMC Neurology. Parkinson’s disease is a progressive neurological